Merck & Co

Merck & Co Revenue

The The revenue of Merck & Co (MRK) as of Nov 11, 2026 is 64.93 B USD. In the previous year, The revenue was 64.17 B USD — a change of 1.18% (higher).

Revenue

64.93 BUSD

YoY

1.18%

Last updated:

In 2025, Merck & Co's sales reached 64.93 B USD, a 1.18% difference from the 64.17 B USD sales recorded in the previous year.

Revenue has compounded at 5.7% per year over the past 19 years to 64.93 B USD.

The Merck & Co Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2023
60.12 B USD
Jan 1, 2024
64.17 B USD
Jan 1, 2025
64.93 B USD
Jan 1, 2026 (e)
67.20 B USD
Jan 1, 2027 (e)
69.46 B USD
Jan 1, 2028 (e)
73.63 B USD
Jan 1, 2029 (e)
74.27 B USD
Jan 1, 2030 (e)
74.80 B USD
The Merck & Co Revenue history
YEARRevenueYoY
est74.80 BUSD+0.71%
est74.27 BUSD+0.87%
est73.63 BUSD+5.99%
est69.46 BUSD+3.37%
est67.20 BUSD+3.50%
64.93 BUSD+1.18%
64.17 BUSD+6.74%
60.12 BUSD+1.40%
59.28 BUSD+21.72%
48.70 BUSD+17.31%
41.52 BUSD+6.13%
39.12 BUSD-7.50%
42.29 BUSD+5.41%
40.12 BUSD+0.79%
39.81 BUSD+0.78%
39.50 BUSD-6.48%
42.24 BUSD-4.08%
44.03 BUSD-6.84%
47.27 BUSD-1.62%
48.05 BUSD+4.48%
45.99 BUSD+67.66%
27.43 BUSD+15.00%
23.85 BUSD-1.44%
24.20 BUSD+6.90%
22.64 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Merck & Co Revenue

Merck & Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
60.12 B USD
2.95 B USD
365.00 M USD
Jan 1, 2024
64.17 B USD
20.22 B USD
17.12 B USD
Jan 1, 2025
64.93 B USD
23.49 B USD
18.25 B USD
Jan 1, 2026 (e)
67.20 B USD
10.46 B USD
6.93 B USD
Jan 1, 2027 (e)
69.46 B USD
30.99 B USD
22.45 B USD
Jan 1, 2028 (e)
73.63 B USD
34.05 B USD
24.93 B USD
Jan 1, 2029 (e)
74.27 B USD
34.49 B USD
24.87 B USD
Jan 1, 2030 (e)
74.80 B USD
34.21 B USD
24.66 B USD

Merck & Co Margins

Merck & Co stock margins

The Merck & Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Merck & Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Merck & Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
73.17 %
4.91 %
0.61 %
Jan 1, 2024
76.32 %
31.51 %
26.68 %
Jan 1, 2025
71.98 %
36.17 %
28.12 %
Jan 1, 2026 (e)
71.98 %
15.56 %
10.32 %
Jan 1, 2027 (e)
71.98 %
44.62 %
32.32 %
Jan 1, 2028 (e)
71.98 %
46.25 %
33.86 %
Jan 1, 2029 (e)
71.98 %
46.44 %
33.49 %
Jan 1, 2030 (e)
71.98 %
45.73 %
32.96 %

Merck & Co Stock analysis

What does Merck & Co do? The company Merck & Co Inc has a long history. It was founded in 1891 by the German pharmacist Friedrich Jacob Merck and is now based in Kenilworth, New Jersey, USA. The company has evolved over time into a globally operating company in the pharmaceutical and chemical industry. Merck & Co Inc's business model is based on the development, production, and marketing of medicines and products for the healthcare industry. The company collaborates with other partners such as universities, other companies, and governments to achieve the best possible scientific progress. Research and development play a very important role in this. Merck is divided into three main areas: The Human Health division, which specializes in the development of prescription drugs and products to improve human health. The second division is Animal Health, which focuses on animal medicines and care products. The third division, Life Science (formerly MilliporeSigma), is dedicated to the development of products and services for biopharmaceutical research and production to facilitate the discovery and manufacturing of medicines. Merck & Co Inc. offers a wide range of products, ranging from prescription medicines to specialty chemicals. Some of the most well-known drugs include Januvia for the treatment of type 2 diabetes and Keytruda, an immuno-oncology drug used in the treatment of various types of cancer. Other well-known drugs from Merck & Co Inc. include Gardasil for the prevention of HPV infections, Propecia for the treatment of male pattern hair loss, and Zetia for the treatment of high cholesterol. The company is extremely innovative and has made significant advances in pharmaceutical research in recent decades. Merck & Co Inc. has won numerous awards over the years, including the "2018 Australian Financial Review Boss Most Innovative Companies Award" and the "2018 Global Energy Award for Technology Innovation". Merck & Co Inc. operates worldwide and has subsidiaries and partnerships in many countries. The company has about 69,000 employees and distributes its products in over 140 countries. Merck & Co Inc.'s products are typically prescription-only and prescribed by doctors and professionals. Overall, Merck & Co Inc. is a company with an impressive history that is now one of the leading companies in the pharmaceutical and chemical industry. Thanks to its innovation and its consistent focus on the needs of patients and healthcare professionals, it is able to successfully meet challenges in the healthcare industry and set new standards. Merck & Co is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Merck & Co's Sales Figures

The sales figures of Merck & Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Merck & Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Merck & Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Merck & Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Merck & Co stock

The revenue of Merck & Co is 64.93 B USD in 2025.

The revenue of Merck & Co changed from 64.17 B USD to 64.93 B USD, representing a 1.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The revenue Merck & Co since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Merck & Co historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Merck & Co

All Key Metrics — Merck & Co